Generic Name and Formulations:
Iohexol 9.7g (equivalent to 4.5g carbon bound iodine); per bottle; pwd for oral soln after reconstitution.
Otsuka America Pharmaceutical, Inc.
Indications for ORALTAG:
For opacification of the gastrointestinal (GI) tract during computed tomography (CT) of the abdomen and pelvis.
Limitations Of use:
Not for diagnostic examination of the GI tract.
Adults and Children:
Administer 20–60mins before imaging. <3yrs: up to 4.5g iodine (1 bottle); max 4.5g total iodine dose. 3–18yrs: up to 9g iodine (<1–2 bottles); max 9g total iodine dose. >18yrs: 4.5–9g iodine (1–2 bottles); max 9g total iodine dose. For higher concentration preparation at lower volumes: see full labeling.
Do not administer Oraltag parenterally; risk of severe reactions (eg, sepsis). Previous reaction to an iodinated contrast agent. Allergic disorders. Have emergency resuscitation equipment and trained personnel available. Elderly. Pregnancy. Nursing mothers: consider pumping and discarding breast milk for 10hrs post-administration.
May alter results of thyroid function tests; if indicated, perform prior to administration.
Radiographic contrast medium.
Nausea, vomiting, diarrhea; hypersensitivity reactions.
Single-use bottle (20oz)—12, 25
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy